Article first published online: 1 OCT 2010
Copyright © 2010 American Association for the Study of Liver Diseases
Volume 52, Issue 6, pages 2192–2205, December 2010
How to Cite
Jonas, M. M., Block, J. M., Haber, B. A., Karpen, S. J., London, W. T., Murray, K. F., Narkewicz, M. R., Rosenthal, P., Schwarz, K. B. and McMahon, B. J. (2010), Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. Hepatology, 52: 2192–2205. doi: 10.1002/hep.23934
The workshop was convened and funded by the Hepatitis B Foundation (www.hepb.org) from its general operating funds.
The Hepatitis B Foundation is supported primarily by federal, state and private foundation grants as well as individual charitable donations. The Foundation also has small, unrestricted educational grants from Bristol-Myers Squibb, Gilead Sciences, Idenix, Merck, and Novartis, but no commercial support was provided for this August 11, 2009, workshop. Barbara A. Haber, research support from Bristol-Myers Squibb, Gilead, and Roche; Joan Block, no disclosures; Maureen M. Jonas, research support from Bristol-Myers Squibb, Gilead, and consulting agreement with Gilead, Novartis, and Roche; Saul J. Karpen, no disclosures; W. Thomas London, no disclosures; Brian McMahon, spouse has 100 shares of GlaxoSmithKline in her IRA; Karen F. Murray, research funding from Gilead and Roche; Michael R. Narkewicz, research funding from GlaxoSmithKline; Philip Rosenthal, research support from Bristol-Myers Squibb, Roche, and speakers bureau with GlaxoSmithKline and Merck; and Kathleen B. Schwarz, research support from Bristol-Myers Squibb, Gilead, Roche, and consulting agreement with Novartis
Potential conflict of interest: Dr. Jonas is a consultant for, and received grants from Novartis. He is a consultant for Roche. He also received grants from Bristol-Myers Squibb and Gilead. Dr. Haber received grants from Bristol-Myers Squibb, Gilead, and Roche. Dr. Murray received grants from Gilead and owns stock in Merck. Dr. Narkewics received grants from Novartis. Dr. Rosenthal advises and received grants from Roche. He is on the speakers' bureau of GlaxoSmithKline and received grants from Bristol-Myers Squibb.
- Issue published online: 23 NOV 2010
- Article first published online: 1 OCT 2010
- Accepted manuscript online: 25 AUG 2010 12:00AM EST
- Manuscript Accepted: 16 AUG 2010
- Manuscript Received: 11 FEB 2010
- 42009;50:661-662. Full guideline posted online at www.aasld.org., . Chronic Hepatitis B: Update 2009. AASLD Practice Guideline. Hepatology
- 6A Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of infants, children, and adolescents. MMWR 2005; 54(RR16): 1-31., , , , , , et al.
- 20Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol 2008; 103: 1421-1426., , , , ,Direct Link:
- 25AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-48., , ,Direct Link:
- 60Epivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
- 62Hepsera [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2009.
- 68Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58( RR-11): 1-166., , , , , , et al.